Financial Advocates Investment Management Sells 14,934 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Financial Advocates Investment Management cut its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 16.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,616 shares of the company’s stock after selling 14,934 shares during the quarter. Financial Advocates Investment Management’s holdings in Gossamer Bio were worth $71,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. raised its position in Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after buying an additional 442,895 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock worth $279,000 after buying an additional 124,913 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Gossamer Bio in the 3rd quarter worth about $67,000. US Bancorp DE purchased a new position in Gossamer Bio in the 3rd quarter worth about $39,000. Finally, Sequoia Financial Advisors LLC raised its position in Gossamer Bio by 26.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after buying an additional 25,000 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Gossamer Bio currently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Up 10.4 %

Gossamer Bio stock opened at $1.17 on Tuesday. The business has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $0.90. The company has a market cap of $265.12 million, a P/E ratio of -3.66 and a beta of 1.81. Gossamer Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.60. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.